scholarly journals In vitro susceptibility of Helicobacter pylori to protolichesterinic acid from the lichen Cetraria islandica.

1997 ◽  
Vol 41 (1) ◽  
pp. 215-217 ◽  
Author(s):  
K Ingolfsdottir ◽  
M A Hjalmarsdottir ◽  
A Sigurdsson ◽  
G A Gudjonsdottir ◽  
A Brynjolfsdottir ◽  
...  
Keyword(s):  
Duodenal Ulcer ◽  
Helicobacter Pylori ◽  
Plant Extracts ◽  
Active Component ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Salt Form ◽  
Traditional Use ◽  
In Vitro Susceptibility

With reference to the traditional use of Cetraria islandica (Iceland moss) for relief of gastric and duodenal ulcer, plant extracts were screened for in vitro activity against Helicobacter pylori. (+)-Protolichesterinic acid, an aliphatic alpha-methylene-gamma-lactone, was identified as an active component. The MIC range of protolichesterinic acid, in free as well as salt form, was 16 to 64 micrograms/ml.

scholarly journals 1592. Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa With Overexpression of AmpC β-Lactamase From Phase 3 Clinical Trials

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S792-S793
Author(s):  
Lynn-Yao Lin ◽  
Dmitri Debabov ◽  
William Chang ◽  
Urania Rappo
Keyword(s):  
Clinical Trials ◽  
Active Agent ◽  
Complicated Urinary Tract Infection ◽  
Carbapenem Resistance ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Control Groups ◽  
In Vitro Susceptibility ◽  
Intra Abdominal Infection

Abstract Background AmpC overproduction is a main mechanism of carbapenem resistance, in the absence of acquired carbapenemases. Ceftazidime-avibactam (CAZ-AVI) has potent in vitro activity against AmpC-producing P. aeruginosa and Enterobacterales that are resistant to carbapenems and other β-lactams. Methods Activity of CAZ-AVI and comparators was evaluated against AmpC-overproducing Enterobacterales (n=77) and P. aeruginosa (n=53) collected from 4 CAZ-AVI clinical trials: RECLAIM (complicated intra-abdominal infection [cIAI]), REPRISE (cIAI/complicated urinary tract infection [cUTI]), RECAPTURE (cUTI) and REPROVE (hospital-acquired pneumonia/ventilator associated pneumonia). In vitro susceptibility of CAZ-AVI and comparators was performed by broth microdilution using ThermoFisher custom panels. CLSI breakpoints were used to determine susceptibility. Quantitative PCR and microarray data were used to characterize presence and expression of AmpC. Clinical response at test of cure was assessed. Results Against 77 AmpC-overproducing Enterobacterales isolates, meropenem-vaborbactam (MVB) (98.7% susceptible [S]), CAZ-AVI (96.1% S), and meropenem (MEM) (96.1% S) had similar in vitro activity (Table), with greater in vitro activity than amikacin (AMK) (84.4% S), gentamicin (61.0% S), and ceftolozane-tazobactam (TZC) (35.1% S). Clinical cures in patients with baseline AmpC-overproducing Enterobacterales were 21/26 (81%) in CAZ-AVI group vs 17/20 (85%) in control groups. Against 53 AmpC-overproducing P. aeruginosa isolates, CAZ-AVI (73.6% S) showed greater in vitro activity than AMK (69.8% S), TZC (58.5% S), and MEM (37.7% S). Clinical cures in patients with baseline AmpC-overproducing P. aeruginosa were 12/14 (86%) in CAZ-AVI group vs 9/12 (75%) in control groups. MIC distributions against the same P aeruginosa isolates were CAZ-AVI (MIC50/90, 4/ >64 µg/mL), MVB (MIC50/90, 8/32 µg/mL), and MEM (MIC50/90, 8/32 µg/mL). Table Conclusion CAZ-AVI was the most active agent against AmpC-overproducing P. aeruginosa with higher proportion of clinical cure than controls. CAZ-AVI was also among the most active agents against AmpC-overproducing Enterobacterales, with >96% isolates susceptible. Disclosures Lynn-Yao Lin, MS, AbbVie (Employee) Dmitri Debabov, PhD, AbbVie (Employee) William Chang, BS, AbbVie (Employee) Urania Rappo, MD, MS, PharmD, Allergan (before its acquisition by AbbVie) (Employee)

scholarly journals 688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S312-S313 ◽  
Author(s):  
Eugenie Basseres ◽  
Julie Miranda ◽  
Anne J Gonzales-Luna ◽  
Travis J Carlson ◽  
Tasnuva Rashid ◽  
...  
Keyword(s):  
Geometric Mean ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Large Collection ◽  
In Vitro Susceptibility ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Abdominal Infections ◽  
Insight Into

Abstract Background Eravacycline is a novel, tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in adults. In clinical trials, patients given eravacycline had a low likelihood of developing Clostridioides difficile infection (CDI). We hypothesized this was likely due, in part, to the in vitro susceptibility of eravacycline to C. difficile. The purpose of this study was to test the in vitro susceptibility of eravacycline vs. comparators on contemporary clinical isolates representing common ribotypes, including isolates with decreased susceptibility to metronidazole and vancomycin. Methods Two hundred and thirty-four isolates from our biobank were selected from the six most common ribotypes (F001, F002, F014-020, F027, F106, and F255). Minimum inhibitory concentrations (MIC) at 24 hours were measured according to CLSI guidelines for eravacycline, vancomycin, metronidazole and fidaxomicin. MICs results were tabulated and are presented as the geometric mean by ribotype. Results Geometric MIC results are shown in Table 1. Eravacycline was the most potent antimicrobial tested followed by fidaxomicin, metronidazole, and vancomycin. Results were consistent amongst all ribotypes, including isolates with reduced susceptibility to vancomycin and metronidazole. Conclusion Eravacycline displayed potent in vitro activity against a large collection of clinical C. difficile isolates. These data provide insight into why patients given eravacycline had a low likelihood of developing CDI and support further research to better understand the use of eravacycline to prevent or potentially treat patients with CDI. Disclosures All authors: No reported disclosures.

scholarly journals In vitro activity of plant extracts against some important plant pathogenic fungi of tomato

2017 ◽  
Vol 11 (06) ◽  
pp. 683-689 ◽  
Author(s):  
James W. Muthomi ◽  
◽  
Geraldin M. W. Lengai ◽  
Maina J. Wagacha ◽  
Rama D. Narla ◽  
...  
Keyword(s):  
Plant Extracts ◽  
Pathogenic Fungi ◽  
Vitro Activity ◽  
Plant Pathogenic Fungi ◽  
In Vitro Activity

scholarly journals In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae

2019 ◽  
Vol 74 (12) ◽  
pp. 3505-3510 ◽  
Author(s):  
Zoltán Tóth ◽  
Lajos Forgács ◽  
Jeffrey B Locke ◽  
Gábor Kardos ◽  
Fruzsina Nagy ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Amphotericin B ◽  
Candida Species ◽  
Sensu Stricto ◽  
Candida Guilliermondii ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Auris ◽  
In Vitro Susceptibility

Abstract Background Rezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species. Methods We determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as Saccharomyces cerevisiae. The activity of rezafungin was compared with that of anidulafungin, caspofungin, micafungin, amphotericin B and fluconazole, using CLSI broth microdilution methodology (Fourth Edition: M27). Results Rezafungin MIC90 values were 0.06 mg/L for Candida albicans (n=125), Candida tropicalis (n=51), Candida dubliniensis (n=22), Candida inconspicua (n=41), Candida sojae (n=10), Candida lipolytica (n=10) and Candida pulcherrima (n=10), 0.12 mg/L for Candida glabrata (n=81), Candida krusei (n=53), Candida kefyr (n=52) and Candida fabianii (n=15), 0.25 mg/L for Candida lusitaniae (n=46) and Candida auris (n=19), 0.5 mg/L for Candida metapsilosis (n=15) and S. cerevisiae (n=21), 1 mg/L for Candida orthopsilosis (n=15) and Candida guilliermondii (n=27) and 2 mg/L for Candida parapsilosis sensu stricto (n=59). Caspofungin MIC90 values were 0.25–2 mg/L for all species, while micafungin and anidulafungin MIC90 values were similar to those of rezafungin. Fluconazole resistance was found in C. albicans (5.6%) and C. glabrata (4.9%); rezafungin was effective against these isolates as well. Amphotericin B MIC values did not exceed 2 mg/L. Conclusions Rezafungin showed excellent in vitro activity against both WT and azole-resistant Candida species, as well as against S. cerevisiae. Rezafungin had similar activity to other echinocandins (excluding caspofungin) against common Candida species and, notably, against clinically relevant uncommon Candida species.

scholarly journals In-vitro activity of azithromycin against intracellular Helicobacter pylori

1996 ◽  
Vol 37 (3) ◽  
pp. 483-489 ◽  
Author(s):  
Kristina Hultén ◽  
Otto Cars ◽  
Eva Hjelm ◽  
Lars Engstrand
Keyword(s):  
Helicobacter Pylori ◽  
Vitro Activity ◽  
In Vitro Activity

In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin

2021 ◽  
Vol 6 (2) ◽  
pp. 149-162
Author(s):  
Robert M Taylor ◽  
James A Karlowsky ◽  
Melanie R Baxter ◽  
Heather J Adam ◽  
Andrew Walkty ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Treatment Options ◽  
Vitro Activity ◽  
Health Concern ◽  
In Vitro Activity ◽  
Bacterial Isolates ◽  
In Vitro Susceptibility ◽  
Broth Microdilution Method ◽  
Tract Infections

Background: Community-acquired pneumonia (CAP) is a significant global health concern. Pathogens causing CAP demonstrate increasing resistance to commonly prescribed empiric treatments. Resistance in Streptococcus pneumoniae, the most prevalent bacterial cause of CAP, has been increasing worldwide, highlighting the need for improved antibacterial agents. Lefamulin, a novel pleuromutilin, is a recently approved therapeutic agent highly active against many lower respiratory tract pathogens. However, to date minimal data are available to describe the in vitro activity of lefamulin against bacterial isolates associated with CAP. Methods: Common bacterial causes of CAP obtained from both lower respiratory and blood specimen isolates cultured by hospital laboratories across Canada were submitted to the annual CANWARD study’s coordinating laboratory in Winnipeg, Canada, from January 2015 to October 2018. A total of 876 bacterial isolates were tested against lefamulin and comparator agents using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method, and minimum inhibitory concentrations (MICs) were interpreted using accepted breakpoints. Results: All S. pneumoniae isolates tested from both respiratory (n = 315) and blood specimens (n = 167) were susceptible to lefamulin (MIC ≤0.5 μg/mL), including isolates resistant to penicillins, clarithromycin, doxycycline, and trimethoprim–sulfamethoxazole. Lefamulin also inhibited 99.0% of Haemophilus influenzae isolates (regardless of β-lactamase production) (99 specimens; MIC ≤2 μg/mL) and 95.7% of methicillin-susceptible Staphylococcus aureus (MSSA) (MIC ≤0.25 μg/mL; 70 specimens) at their susceptible breakpoints. Conclusions: Lefamulin demonstrated potent in vitro activity against all respiratory isolates tested and may represent a significant advancement in empiric treatment options for CAP.

scholarly journals In vitro activity of Amazon plant extracts against Enterococcus faecalis

2014 ◽  
Vol 45 (3) ◽  
pp. 769-779 ◽  
Author(s):  
Adriana Lígia de Castilho ◽  
Juliana Paola Correa da Silva ◽  
Cintia Helena Coury Saraceni ◽  
Ingrit Elida Collantes Díaz ◽  
Mateus Luís Barradas Paciencia ◽  
...  
Keyword(s):  
Enterococcus Faecalis ◽  
Plant Extracts ◽  
Vitro Activity ◽  
In Vitro Activity
Sign in / Sign up

Export Citation Format

Share Document